93. New Insights into the Epidemiology and Prevention of Clostridium difficile Infection
Friday, October 4, 2013: 8:30 AM-10:00 AM
Room: The Moscone Center: 135 (Hall E)

Learning Objectives:

At the conclusion of this session, participants will be able to:

  • discuss controversies related to determination of routes of Clostridium difficile (C. difficile) transmission, including the roles of asymptomatic carriers, community transmission, and accuracy of diagnostic tests
  • describe the role of environmental cleaning and disinfection in the control of C. difficile transmission in healthcare settings
  • summarize challenges and opportunities to hospitals associated with  public reporting of C. difficile infection rates

Target Audience: researchers, public health practitioners, members-in-training, infectious diseases physicians, infection preventionists, hospital epidemiologists, hospital administrators, health care workers, fellows, epidemiologists, clinicians, academicians

Tracks: Epidemiology and Infection Control

Moderators:  Thomas G. Fraser, MD, FSHEA, Cleveland Clinic Foundation and L. Clifford Mcdonald, MD, FSHEA, Centers for Disease Control and Prevention

CME Credits: Maximum of 1.5 hours of AMA PRA Category 1 CreditTM

ACPE Credits: No CPE credit is offered for this session.

ACPE Number:


T. G. Fraser, None

L. C. Mcdonald, None

M. Wilcox, Actelion: Consultant and Research Contractor, Consulting fee and Research support
Astellas: Consultant and Research Contractor, Consulting fee and Research support
Biomerieux: Research Contractor, Research support
Cubist: Consultant and Research Contractor, Consulting fee and Research support
Pfizer: Consultant, Research Contractor and Speaker's Bureau, Consulting fee, Research support and Speaker honorarium
Summit: Research Contractor, Research support
The Medcine Company: Research Contractor, Research support
Astra Zeneca: Consultant, Consulting fee
Bayer: Consultant, Consulting fee
Durata: Consultant, Consulting fee
J&J: Consultant, Consulting fee
Merck: Consultant, Consulting fee
Nabriva: Consultant, Consulting fee
Novacta: Consultant, Consulting fee
Novartis: Consultant, Consulting fee
Optimer: Consultant, Consulting fee
Sanofi-Pasteur: Consultant, Consulting fee
The Medicine Company: Consultant, Consulting fee
VH Squared: Consultant, Consulting fee
Viropharma: Consultant, Consulting fee

C. J. Donskey, 3M: Consultant, Consulting fee
GOJO: Collaborator, Research support
STERIS: Consultant, Speaker honorarium
EcoLab: Grant Investigator, Research grant

D. P. Calfee, None

See more of: Symposium

Findings in the abstracts are embargoed until 12:01 a.m. PST, Oct. 2nd with the exception of research findings presented at the IDWeek press conferences.